12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Firdapse amifampridine 3 regulatory update

The Scottish Medicines Consortium recommended against the use of Firdapse amifampridine from BioMarin on the National Health Service (NHS) in Scotland to treat Lambert-Eaton myasthenic syndrome (LEMS) - its approved...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >